Antiphospholipid Syndrome

CHI Formulary Treatment Algorithm




Treatment Algorithm – December 2023

Supporting treatment algorithm for the clinical management of Antiphospholipid Syndrome (APS)

Figure 1 outlines a comprehensive treatment algorithm for Antiphospholipid Syndrome (APS) aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Antiphospholipid Syndrome (APS)** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at <u>https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx</u>

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.



aPL = antiphospholipid antibodies; CV = cardiovascular; DOAC = direct oral anticoagulant; INR = international normalized ratio; LDA = low dose aspirin; LMWH = low molecular weight heparin; VKA = vitamin k antagonist. Recommendation grade: B: consistent level 2 or 3 studies, or extrapolations from level 1 studies; C: level 4 studies or extrapolations from level 2 or 3 studies; D: level 5 evidence or troublingly inconsistent or inconclusive studies of any level.

* Surgery, pregnancy/post-partum, and immobilization.

1

¹ Ghembaza A, Saadoun D. Management of antiphospholipid syndrome. Biomedicines. 2020;8(11):1-17. doi:10.3390/biomedicines8110508